RA Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

RA Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47M	Sell	5,049,779 -603,432	-11%	-$5.25M	0.5%	36
2025 Q4	$42.4M	Buy	5,653,211 +1,090,000	+24%	+$11.1M	0.43%	39
2025 Q3	$39.7M	Hold	4,563,211	–	–	0.49%	33
2025 Q2	$16.9M	Hold	4,563,211	–	–	0.29%	40
2025 Q1	$14.7M	Hold	4,563,211	–	–	0.25%	57
2024 Q4	$25.4M	Sell	4,563,211 -535,000	-10%	-$4.2M	0.34%	49
2024 Q3	$55.1M	Hold	5,098,211	–	–	0.64%	35
2024 Q2	$107M	Buy	5,098,211 +46,700	+0.9%	+$1.17M	1.42%	21
2024 Q1	$161M	Buy	5,051,511 +888,300	+21%	+$22.7M	2.05%	12
2023 Q4	$84.3M	Hold	4,163,211	–	–	1.32%	22
2023 Q3	$53M	Buy	4,163,211 +1,093,680	+36%	+$18.3M	1.04%	28
2023 Q2	$55.5M	Buy	+3,069,531	New	+$56.5M	1.05%	29

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RA Capital Management's FDMT Position: Q1 2026 in Review

RA Capital Management reduced its 4D Molecular Therapeutics (FDMT) stake by 11% in Q1 2026, selling an estimated $5.25M and leaving 5,049,779 shares worth $47M. The position accounts for 0.5% of the portfolio, ranked #36.

RA Capital Management first reported a position in FDMT in Q2 2023 and has held it in 12 quarters since. The position peaked at $161M in Q1 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

RA Capital Management held 5,049,779 shares of 4D Molecular Therapeutics worth $47M as of Q1 2026.
RA Capital Management sold 603,432 4D Molecular Therapeutics shares in Q1 2026, an estimated $5.25M.
4D Molecular Therapeutics made up 0.5% of RA Capital Management's portfolio in Q1 2026, its #36 holding.
RA Capital Management first reported a position in 4D Molecular Therapeutics in Q2 2023 and has held it in 12 quarters since.
RA Capital Management's 4D Molecular Therapeutics position peaked at $161M in Q1 2024.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.